肠道菌群介导胰腺癌化疗耐药作用机制的研究进展

Research progress on the mechanism of gut microbiota-mediated chemoresistance in pancreatic cancer

摘要:

胰腺癌化疗耐药机制极为复杂，近年来研究发现肠道菌群在其中扮演着重要角色。肠道菌群可通过直接代谢药物，改变药物的活性和浓度，影响化疗药物对肿瘤细胞的作用效果，同时，还能调控肿瘤微环境，包括影响免疫细胞功能、改变细胞因子分泌等，进而参与胰腺癌化疗耐药过程。该文聚焦肠道菌群在胰腺癌化疗耐药中的作用，全面总结了其在耐药发生、发展中的具体表现和可能的作用机制，并且还系统整理了运用抗生素、噬菌体、粪菌移植等方式来调节肠道菌群组成在胰腺癌化疗耐药调节方面的相关研究，希望能为改善胰腺癌化疗耐药状况及实现精准治疗提供新的思路。

Abstract:

The mechanisms underlying chemoresistance in pancreatic cancer are extremely complex. Recent research has revealed that the gut microbiota plays a significant role in this process. The gut microbiota can directly metabolize chemotherapeutic drugs, altering their activity and concentration, thereby affecting the drugs' efficacy against tumor cells. Concurrently, it can regulate the tumor microenvironment, including influencing immune cell functions and altering cytokine secretion, which further contributes to the development of chemoresistance in pancreatic cancer. This review focuses on the role of the gut microbiota in pancreatic cancer chemoresistance, comprehensively summarizing its specific manifestations and potential mechanisms in the onset and progression of drug resistance. Furthermore, it systematically consolidates studies on modulating gut microbiota composition through approaches such as antibiotics, bacteriophages, and fecal microbiota transplantation to regulate chemoresistance in pancreatic cancer. This work aims to provide new insights for improving the management of chemoresistance in pancreatic cancer and advancing precision therapy.